



## Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective **October 28, 2021**, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than the Generic Program:

- **Renvela tablet** will be **ADDED** to the program.
- **Atripla, Novolog vial, and Truvada** have been **REMOVED** from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require ‘Dispense as Written’ (DAW) or ‘Brand Medically Necessary’ on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

### IMPORTANT BILLING INFORMATION

Pursuant to this program prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of ‘1’; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and “*Brand Medically Necessary*” on the prescription.

### List of Brand Name Drugs included in this program\* (updated 10/13/2021)

Advair Diskus	Depakote Sprinkle	Rapamune solution
Alphagan P 0.15%	Diclegis	Renagel**
Amitiza	Entocort EC**	<b>Renvela tablet</b>
Androgel pump & packets	Exelon Patch	Retin-A cream
Apriso	Firvanq	Suboxone film
Azopt	Focalin XR	Symbicort
Bethkis	Humalog U100 vial & 50-50 KwikPen	Tecfidera
Catapres-TTS	Kitabis Pak	Tegretol suspension
Cellcept suspension	Lialda	Tracleer tablet
Ciprodex	Novolog 100u/ml FlexPen & Mix 70/30 FlexPen	Xeloda
Concerta	Nuvaring	Zovirax cream
Copaxone 20mg	ProAir HFA	

\*List is subject to change \*\*Entocort EC, Renagel, added based on [July 15, 2021 DURB recommendations](#)

**Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.**